Novel therapies for epilepsy in the pipeline
Novel therapies for epilepsy in the pipeline
复制标题
DOI：
10.1016/j.yebeh.2019.04.042
复制
发表时间：
2019-08-01
影响因子：
2.6
通讯作者：
Asadi-Pooya, Ali A.
中科院分区：
文献类型：
--
作者：
Mesraoua, Boulenouar;Deleu, Dirk;Asadi-Pooya, Ali A.
尽管有许多抗癫痫药物(AED)(旧的和新开发的)可用，并且如最近所示，它们在治疗失控发作的患者中得到了优化，但超过30%的癫痫患者继续经历癫痫发作和耐药癫痫；这些患者的管理对癫痫专家和研究人员来说是一个真正的挑战。因此，研究和发现治疗难治性癫痫的新方法是极其重要的。本文将就P-糖蛋白(P-gp)抑制剂、基因治疗、干细胞治疗、传统和新型抗癫痫药物、精确医学以及儿童癫痫脑病治疗进展等方面的创新方法进行讨论，这些治疗方式为难治性癫痫患者的治疗开辟了新的视野。(C)2019 Elsevier Inc.保留所有权利。
Despite the availability of many antiepileptic drugs (AEDs) (old and newly developed) and, as recently suggested, their optimization in the treatment of patients with uncontrolled seizures, more than 30% of patients with epilepsy continue to experience seizures and have drug-resistant epilepsy; the management of these patients represents a real challenge for epileptologists and researchers. Resective surgery with the best rates of seizure control is not an option for all of them; therefore, research and discovery of new methods of treating resistant epilepsy are of extreme importance. In this article, we will discuss some innovative approaches, such as P-glycoprotein (P-gp) inhibitors, gene therapy, stem cell therapy, traditional and novel antiepileptic devices, precision medicine, as well as therapeutic advances in epileptic encephalopathy in children; these treatment modalities open up new horizons for the treatment of patients with drug-resistant epilepsy. (C) 2019 Elsevier Inc. All rights reserved.